Cue Biopharma (CUE) CEO adds pre-funded and common stock warrants
Rhea-AI Filing Summary
Cue Biopharma Chief Executive Officer Shao-Lee Lin, through the Shao-Lee Lin Trust dated March 13, 2023, reported acquiring 90,906 pre-funded warrants and 45,453 common stock warrants on June 1, 2026. These securities were issued in a private placement under an April 30, 2026 securities purchase agreement at $11.00 per pre-funded warrant plus accompanying half-share warrant. The pre-funded warrants have a $0.001 exercise price and no expiration; the common stock warrants have an $11.00 exercise price and expire on May 4, 2031. Both series became exercisable on June 1, 2026 after stockholder approval, and the board approved the transactions under Rule 16b-3. The amendment corrects only the previously reported transaction code.
Positive
- None.
Negative
- None.
Insider Trade Summary
2 transactions reported
Mixed
2 txns
Insider
Lin Shao-Lee
Role
Chief Executive Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Pre-Funded Warrants (Right to Buy) F1, F3, F2, F4 | 90,906 | $11.00 | $1000K |
| Grant/Award | Common Stock Warrants (Right to Buy) F1, F3, F4 | 45,453 | -- | -- |
Holdings After Transaction:
Pre-Funded Warrants (Right to Buy) — 90,906 shares (Indirect, See footnote);
Common Stock Warrants (Right to Buy) — 45,453 shares (Indirect, See footnote)
Footnotes (4)
- F1. This amendment is filed solely to correct the transaction code reported in Column 4 of Table II. The transactions reported herein were approved by the Issuer's board of directors pursuant to Rule 16b-3 under the Securities Exchange Act of 1934, as amended, prior to the issuance of the applicable securities. All other information in the original filing remains unchanged.
- F2. The securities do not have an expiration date.
- F3. On April 30, 2026, the Issuer entered into a securities purchase agreement (the "Purchase Agreement") with certain accredited investors, including the Reporting Person. Pursuant to the terms of the Purchase Agreement, the Issuer issued and sold pre-funded warrants and accompanying warrants to purchase shares of common stock in a private placement that closed on May 4, 2026. The purchase price for each pre-funded warrant and accompanying warrants to purchase one-half of one share of common stock was $11.00. The pre-funded warrants and accompanying warrants became exercisable on June 1, 2026, following approval by the Issuer's stockholders of the issuance of common stock upon exercise of the pre-funded warrants and accompanying warrants in accordance with applicable listing rules of the Nasdaq Stock Market, including Nasdaq Listing Rule 5636, at the Issuer's Special Meeting of Stockholders held on June 1, 2026.
- F4. The securities are held by the Shao-Lee Lin Trust, DTD 3/13/2023.
Key Figures
Pre-funded warrants acquired: 90906.0000 pre-funded warrants
Pre-funded warrant exercise price: 0.0010 per share
Common stock warrants acquired: 45453.0000 common stock warrants
+3 more
6 metrics
Pre-funded warrants acquired
90906.0000 pre-funded warrants
Derivative acquisition by Shao-Lee Lin via trust on 2026-06-01
Pre-funded warrant exercise price
0.0010 per share
Exercise price of pre-funded warrants for Cue Biopharma common stock
Common stock warrants acquired
45453.0000 common stock warrants
Derivative acquisition by Shao-Lee Lin via trust on 2026-06-01
Unit purchase price
11.0000 per pre-funded warrant plus accompanying warrant
Price under April 30, 2026 securities purchase agreement in private placement
Common warrant exercise price
11.0000 per share
Exercise price of Cue Biopharma common stock under acquired warrants
Common warrant expiration date
2031-05-04
Expiration date of the acquired common stock warrants
Key Terms
Pre-Funded Warrants, securities purchase agreement, Rule 16b-3, Nasdaq Listing Rule 5636
4 terms
Pre-Funded Warrants financial
"The Issuer issued and sold pre-funded warrants and accompanying warrants"
Pre-funded warrants are financial instruments that give investors the right to purchase a company's stock at a set price, but with most or all of the purchase price paid upfront. They function like a coupon or gift card for stock, allowing investors to buy shares later at a fixed price, which can be beneficial if they want to avoid future price increases. This makes them important for investors seeking flexibility and certainty in their investment plans.
securities purchase agreement financial
"On April 30, 2026, the Issuer entered into a securities purchase agreement"
A securities purchase agreement is a written contract between a buyer and a seller outlining the terms for buying or selling financial assets such as stocks or bonds. It specifies details like the price, quantity, and conditions of the transaction, similar to a shopping list with agreed-upon terms. For investors, it provides clarity and legal protection when transferring ownership of these financial instruments.
Rule 16b-3 regulatory
"approved by the Issuer's board of directors pursuant to Rule 16b-3"
Rule 16b-3 is a Securities and Exchange Commission regulation that exempts certain routine, pre-approved transactions by company insiders from automatic liability for short-term trading profits. It acts like a safe harbor: if an insider follows a formal plan or the board approves specific transactions in advance, profits from buying and selling company stock within six months are not automatically reclaimed. Investors care because the rule clarifies when insider trades are permissible and reduces uncertainty about potential clawbacks.
Nasdaq Listing Rule 5636 regulatory
"in accordance with applicable listing rules of the Nasdaq Stock Market, including Nasdaq Listing Rule 5636"
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What insider transactions did Cue Biopharma (CUE) report for CEO Shao-Lee Lin?
Cue Biopharma CEO Shao-Lee Lin reported acquiring 90,906 pre-funded warrants and 45,453 common stock warrants on June 1, 2026 through a trust. These derivative securities were issued in a private placement and became exercisable after stockholder approval on the same date.
What are the key terms of the pre-funded warrants reported by CUE?
The pre-funded warrants total 90,906 and were purchased as part of a unit priced at $11.00. They carry an exercise price of $0.001 per share, have no expiration date, and became exercisable on June 1, 2026 following Cue Biopharma stockholder approval.
What are the terms of the common stock warrants acquired in the Cue Biopharma (CUE) transaction?
Shao-Lee Lin acquired 45,453 common stock warrants, each with an exercise price of $11.00 and an expiration date of May 4, 2031. These warrants were issued with the pre-funded warrants and became exercisable on June 1, 2026 after stockholder approval.
How were the Cue Biopharma (CUE) warrants held and who is the owner of record?
Both the pre-funded warrants and common stock warrants are held indirectly through the Shao-Lee Lin Trust dated March 13, 2023. Shao-Lee Lin is the reporting person, but legal title to the securities resides with this trust rather than directly with the individual.
What does the Form 4/A amendment for Cue Biopharma (CUE) change?
The amendment states it was filed solely to correct the transaction code in the derivative securities table. All economic terms, quantities, dates, and ownership details from the original report remain unchanged, and the transactions had been approved under Rule 16b-3.